Articles by Suzanne Z. Mattingly - Pharmaceutical Executive

ADVERTISEMENT

Articles by Suzanne Z. Mattingly

Biomarkers Come of Age

In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened—and what comes next.
Sep 1, 2005

In a few years' time, or so the conventional wisdom goes, personalized medicine will become a reality, and many (or even most) new drugs will come to market supported by tests that will help physicians make the decision of who gets what drug, what's the appropriate dose, and who's in the greatest danger of serious side effects—all based on a better understanding of biological processes and newly available data from testing at the molecular level to characterize patients and disease. We're not there yet, of course. To date only a handful of drugs are accompanied by molecular-level diagnostic tests. At the 2005 Molecular Medicine Tri-Conference, Ian Massey, PhD, senior vice president and head of research and preclinical development at Roche, expressed the opinion that molecular diagnostics will only affect a few medicines in the near to mid-term.

ADVERTISEMENT

Click here